Vanguard Group Inc. lifted its stake in Maximus, Inc. (NYSE:MMS) by 2.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,669,026 shares of the health services provider’s stock after acquiring an additional 130,839 shares during the quarter. Vanguard Group Inc. owned approximately 8.74% of Maximus worth $355,052,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in the stock. Northern Trust Corp increased its position in shares of Maximus by 1.1% in the second quarter. Northern Trust Corp now owns 1,175,219 shares of the health services provider’s stock valued at $73,603,000 after acquiring an additional 12,977 shares during the last quarter. D.A. Davidson & CO. increased its position in shares of Maximus by 0.9% in the second quarter. D.A. Davidson & CO. now owns 43,960 shares of the health services provider’s stock valued at $2,753,000 after acquiring an additional 387 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Maximus in the second quarter valued at about $1,198,000. UBS Asset Management Americas Inc. increased its position in shares of Maximus by 1.7% in the second quarter. UBS Asset Management Americas Inc. now owns 34,898 shares of the health services provider’s stock valued at $2,186,000 after acquiring an additional 592 shares during the last quarter. Finally, Trilogy Global Advisors LP acquired a new stake in shares of Maximus in the second quarter valued at about $17,325,000. 97.23% of the stock is currently owned by institutional investors and hedge funds.
MMS has been the topic of a number of recent research reports. Zacks Investment Research raised Maximus from a “hold” rating to a “buy” rating and set a $73.00 target price on the stock in a research report on Wednesday. Robert W. Baird initiated coverage on Maximus in a research report on Sunday, September 3rd. They issued a “neutral” rating on the stock. BidaskClub downgraded Maximus from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 6th. Maxim Group set a $66.00 target price on Maximus and gave the company a “hold” rating in a research report on Thursday, August 3rd. Finally, Canaccord Genuity downgraded Maximus from a “buy” rating to a “hold” rating and set a $62.00 target price on the stock. in a research report on Tuesday, July 4th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $63.14.
Maximus, Inc. (NYSE MMS) opened at 65.61 on Friday. The firm has a market cap of $4.26 billion, a P/E ratio of 21.03 and a beta of 1.36. The firm’s 50-day moving average price is $62.40 and its 200-day moving average price is $61.82. Maximus, Inc. has a 12 month low of $43.69 and a 12 month high of $65.87.
Maximus (NYSE:MMS) last posted its earnings results on Thursday, August 3rd. The health services provider reported $0.79 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.76 by $0.03. Maximus had a net margin of 8.43% and a return on equity of 25.08%. The firm had revenue of $600.40 million for the quarter, compared to analysts’ expectations of $614.12 million. During the same quarter last year, the firm earned $0.79 EPS. The company’s quarterly revenue was down 2.7% compared to the same quarter last year. On average, equities research analysts expect that Maximus, Inc. will post $3.13 EPS for the current fiscal year.
In other Maximus news, President Bruce Caswell sold 8,000 shares of Maximus stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $62.21, for a total transaction of $497,680.00. Following the transaction, the president now owns 35,904 shares of the company’s stock, valued at approximately $2,233,587.84. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, General Counsel David Francis sold 3,000 shares of Maximus stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $65.28, for a total transaction of $195,840.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 160,403 shares of company stock worth $9,912,181. Insiders own 3.10% of the company’s stock.
Maximus Company Profile
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
Want to see what other hedge funds are holding MMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maximus, Inc. (NYSE:MMS).
Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.